1. Al-Essa, R. (2014, May 12–14). Kuwait conference and exhibition on National Pharmacovigilance Strategies. Ministry of Health of Kuwait and the Executive Board of Health Ministers’ Council for GCC States. Crowne Plaza Hotel, State of Kuwait.
2. Alessa, R., Salek, S., & Walker, S. (2011). The development of a strategic plan for strengthening the drug regulation in the Gulf region. Script Regulatory Affairs. Informa UK Ltd.
http://cirsci.org/sites/default/files/SRA_Sept_Al-Essa_Salek_Walker_The%20development%5B1%5D.pdf
.
3. Bahri, P., & Harrison-Woolrych, M. (2012). Focusing on risk communication about medicines: Why now? Drug Safety: An International Journal of Medical Toxicology and Drug Experience, 35(11), 971–975.
4. Bouder, F. (2011). Benefit/risk communication by the European Medicines Agency: A study of influential stakeholders’ expectations and attitudes. Maastricht: Department of Technology and Society Studies, Maastricht University.
5. Chused, A. E., Kuperman, G. J., & Stetson, P. D. (2008). Alert override reasons: A failure to communicate. AMIA Annual Symposium Proceedings/AMIA Symposium AMIA Symposium, 111–5.